COMMUNIQUÉS West-GlobeNewswire

Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
25/04/2025
TARPON SPRINGS, Fla., April 25, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual [...]
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
25/04/2025
TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat [...]
Managers’ transactions
25/04/2025
April 25, 2025 Announcement no. 13 Managers’ transactions In connection with the completion of BioPorto A/S’ directed issue as described in company announcement no. 12, BioPorto A/S has received notification pursuant to [...]
Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
25/04/2025
Vancouver, Canada, April 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes
25/04/2025
April 25, 2025 Announcement no. 12 BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes Completion of share capital increase COPENHAGEN, DENMARK, April 25, 2025 (GLOBE [...]
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
25/04/2025
SHANGHAI, April 25, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Flush Factor Plus Reviews (Complaints & Side Effects) Investigative Report on Its Effectiveness for Joint Health!
25/04/2025
MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- Flush Factor Plus is a natural dietary supplement that claims to support fluid retention and promote joint mobility and flexibility. Knee pain and joint issues due to improper [...]
Best Over the Counter (OTC) Appetite Suppressant Pills 2025: Strongest Natural Hunger Control Suppressants from PhenQ
25/04/2025
Curb cravings and support effective hunger control with the best over-the-counter appetite suppression pills of 2025. Discover natural OTC solutions designed to boost energy, reduce snacking, and enhance portion control [...]
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
25/04/2025
Raanana, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
25/04/2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]
Media Advisory - 2025 Virtual Reality Expo: Accelerating Innovation in Healthcare
25/04/2025
MONTREAL, April 25, 2025 (GLOBE NEWSWIRE) -- Media representatives are invited to the 2025 edition of the VR Expo: Accelerating Innovation in Health Care , an immersive event that explores the potential of virtual [...]
Avis aux médias - Exposition Réalité Virtuelle 2025 : Accélérer l'innovation en matière de soins de santé
25/04/2025
MONTRÉAL, 25 avr. 2025 (GLOBE NEWSWIRE) -- Les représentants des médias sont cordialement invités à l’édition 2025 de la RV Expo : accélérer l’innovation en matière de soins de santé, un événement immersif qui explore [...]
BPGbio Highlights Groundbreaking Data on BPM31510 for Mitochondrial Diseases at the Inaugural Mitochondrial Transplantation and Next Generation Therapeutics Conference
25/04/2025
Advanced Spatial Quinomics Study Reveals Novel Insights into the Therapeutic Impact of BPM31510, Being Studied as a Potential Treatment for Primary CoQ10 Deficiency and Other Mitochondrial Diseases BOSTON, April 25, [...]
CPOINT Capital Corp. Announces Changes to Holdings in Conavi Medical Corp.
25/04/2025
TORONTO, April 25, 2025 (GLOBE NEWSWIRE) -- CPOINT Capital Corp. (“ CPOINT ”) announces that, on April 23, 2025, it and its affiliate Juno Pharmaceuticals LP (“ Juno ”) acquired 1,875,000 common shares (the “ Common [...]
Philips provides update on the Annual General Meeting of Shareholders 2025 Agenda
25/04/2025
April 25, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) provides an update on the Annual General Meeting 2025 which has been convened on March 24, 2025 (AGM). As previously announced, the AGM [...]
A Place to Heal: Virtue Recovery Center Stands with Veterans and Families Across the United States
25/04/2025
LAS VEGAS, April 25, 2025 (GLOBE NEWSWIRE) -- When military service ends, many Veterans find themselves facing a new kind of battle — one marked by PTSD, addiction, and the struggle to reconnect with daily life. With an [...]
Elixir Medical Announces First Use of LithiX Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Asia Pacific at Cardiac Vascular Sentral Kuala Lumpur (CVSKL), Malaysia
25/04/2025
First cases completed by Dr. Tamil Selvan Muthusamy, MD, and Dr. Rosli Mohd Ali, MD, and transmitted live at TCTAP Congress in Seoul, Korea. Novel IVL technology designed to deliver calcium fragmentation for treatment [...]
Best Thermogenic Fat Burner Supplements 2025: Top Fat Burning Pills for Weight Loss From PhenQ
25/04/2025
Clinically-backed thermogenic fat burners accelerate metabolism, ignite fat loss, and curb appetite—PhenQ leads 2025’s top fat-burning supplements for men and women aiming for sustainable weight loss results. NEW YORK, [...]
TREMFYA® (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease
25/04/2025
The first a approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis, 1 , 2 , 3 , 4 , 5 guselkumab showed statistically higher rates of endoscopic [...]

Pages